267 related articles for article (PubMed ID: 29883857)
1. Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment.
El Rassy E; Botticella A; Kattan J; Le Péchoux C; Besse B; Hendriks L
Cancer Treat Rev; 2018 Jul; 68():69-79. PubMed ID: 29883857
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
[TBL] [Abstract][Full Text] [Related]
4. Combination treatments with immunotherapy in brain metastases patients.
Henon C; Remon J; Hendriks LE
Future Oncol; 2020 Aug; 16(23):1691-1705. PubMed ID: 32412817
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
Namba Y; Kijima T; Yokota S; Niinaka M; Kawamura S; Iwasaki T; Takeda Y; Kimura H; Okada T; Yamaguchi T; Nakagawa M; Okumura Y; Maeda H; Ito M
Clin Lung Cancer; 2004 Sep; 6(2):123-8. PubMed ID: 15476598
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.
Wei Y; Xu Y; Wang M
Chin Med J (Engl); 2023 Jul; 136(13):1523-1531. PubMed ID: 37106555
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?
Rossi S; Finocchiaro G; Marchetti S; Toschi L; Santoro A
Immunotherapy; 2018 Apr; 10(5):403-410. PubMed ID: 29473467
[TBL] [Abstract][Full Text] [Related]
9. The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
Tracz JA; Donnelly BM; Ngu S; Vojnic M; Wernicke AG; D'Amico RS
J Neurooncol; 2023 May; 163(1):1-14. PubMed ID: 37086369
[TBL] [Abstract][Full Text] [Related]
10. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
Sekine A; Satoh H
Med Oncol; 2017 Jul; 34(7):121. PubMed ID: 28555261
[TBL] [Abstract][Full Text] [Related]
11. Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis.
Nigen B; Goronflot T; Herbreteau G; Mathiot L; Sagan C; Raimbourg J; Bennouna J; Thillays F; Pons-Tostivint E
Lung Cancer; 2023 Oct; 184():107321. PubMed ID: 37586178
[TBL] [Abstract][Full Text] [Related]
12. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Rassy E; Mezquita L; Remon J; Besse B
Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
[TBL] [Abstract][Full Text] [Related]
13. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis.
Ceresoli GL; Reni M; Chiesa G; Carretta A; Schipani S; Passoni P; Bolognesi A; Zannini P; Villa E
Cancer; 2002 Aug; 95(3):605-12. PubMed ID: 12209754
[TBL] [Abstract][Full Text] [Related]
14. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
[TBL] [Abstract][Full Text] [Related]
15. Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases.
Hsiao SH; Chung CL; Chou YT; Lee HL; Lin SE; Liu HE
Lung Cancer; 2013 Nov; 82(2):319-23. PubMed ID: 24018025
[TBL] [Abstract][Full Text] [Related]
16. [Multimodal Treatment of Non-Small Cell Lung Cancer with Cerebral Metastases].
Kudelin N; Bölükbas S; Schirren J
Zentralbl Chir; 2015 Jun; 140(3):328-33. PubMed ID: 26114639
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma.
Kourie HR; Kanaan H; Awada G; Awada AH
Future Oncol; 2017 May; 13(12):1097-1103. PubMed ID: 28326837
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
Chamberlain MC; Baik CS; Gadi VK; Bhatia S; Chow LQ
Neuro Oncol; 2017 Jan; 19(1):i1-i24. PubMed ID: 28031389
[TBL] [Abstract][Full Text] [Related]
20. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
Gui Q; Liu J; Li D; Xu C
World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
